Phase III study of Zevalin [ibritumomab tiuxetan Y-90] and BEAM [carmustine, etoposide, cytarabine and melphalan] compared with BEAM alone prior to autologous hematopoietic stem cell transpl. [transplantation] in pts [patients] relapse of non-Hodgkins lymphoma

Trial Profile

Phase III study of Zevalin [ibritumomab tiuxetan Y-90] and BEAM [carmustine, etoposide, cytarabine and melphalan] compared with BEAM alone prior to autologous hematopoietic stem cell transpl. [transplantation] in pts [patients] relapse of non-Hodgkins lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2011 Status changed from not yet recruiting to active, no longer recruiting.
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top